← 返回

新兴免疫治疗在前列腺癌治疗中的应用:进展、困境与前景

英文原题:The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.

查看英文原题

The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise.

PubMed 2025/03/12(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近年来,采用免疫疗法治疗癌症的趋势日益明显。癌症疫苗、免疫检查点抑制剂和过继细胞疗法已使部分恶性肿瘤治疗取得显著进展。由于缺少能够改善转移性去势抵抗性前列腺癌(mCRPC)预后的有效辅助治疗,研究者正在探索上述方法作为晚期前列腺癌(PCa)的潜在治疗选择。免疫治疗策略在 PCa 治疗中尚未取得重大进展,主要原因是该恶性肿瘤的肿瘤微环境具有抑制性且突变负荷较低。因此,研究者正尝试优化免疫疗法设计和疗效,并将其与其他治疗方式整合,以应对这些挑战。迄今研究也显示出潜在临床获益。本综述全面分析免疫治疗技术在 PCa 治疗中的应用,评估其优势和障碍,旨在帮助医疗专业人员和学者全面了解该领域进展。

展开英文摘要原文

In recent years, there has been a growing trend towards the utilization of immunotherapy techniques for the treatment of cancer. Some malignancies have acquired significant progress with the use of cancer vaccines, immune checkpoint inhibitors, and adoptive cells therapy. Scholars are exploring the aforementioned methods as potential treatments for advanced prostate cancer (PCa) due to the absence of effective adjuvant therapy to improve the prognosis of metastatic castration-resistant prostate cancer (mCRPC). Immunotherapy strategies have yet to achieve significant advancements in the treatment of PCa, largely attributed to the inhibitory tumor microenvironment and low mutation load characteristic of this malignancy.

Hence, researchers endeavor to address these challenges by optimizing the design and efficacy of immunotherapy approaches, as well as integrating them with other therapeutic modalities. To date, studies have also shown potential clinical benefits. This comprehensive review analyzed the utilization of immunotherapy techniques in the treatment of PCa, assessing their advantages and obstacles, with the aim of providing healthcare professionals and scholars with a comprehensive understanding of the progress in this field.

论文信息

作者
Che J、Liu Y、Liu Y、Song J、Cui H、Feng D、Tian A、Zhang Z
单位
Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, The Second Clinical Medical College of Binzhou Medical University, Yantai, Shandong, China.China
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 40145100 · DOI 10.3389/fimmu.2025.1544882